VANCOUVER, BC, Feb. 06, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Phyto Pharma Inc. ( www.phytopharma.ca ), a Vancouver, British Columbia based phytopharmaceutical and intellectual property holding company with operations in three United States jurisdictions, today announced the initiation of its’ genetic strain mapping program for the Company’s proprietary CBD nutraceutical product lines.
Innovation within the space is taking off with CBD being added into beauty, pet, skin care, drinks, and fitness products. Phyto Pharma expects to be singled out within the wellness sector for its’ unique, closed loop and innovative wellness model. The Company contracts for the production of specific strains of high CBD biomass through strategic farm tolling operations, incorporates proprietary extraction methods for CBD oil and finally, engages in the formulation, development, and commercialization of cannabinoid-based medications.
Phyto Pharma brands including Phytocine ™ and Rehab Rx ™ are manufactured from proprietary strains of whole plant hemp extracts, containing a full spectrum of phytocannabinoids, including CBD, terpenes, flavonoids, and other valuable hemp compounds.
“The level of investment interest in the cannabis industry soared in 2018,” said Tom Zuber, managing partner of the law firm, Zuber, Lawler & Del Duca LLP, and he expects that to continue. “We see a year of increased M&A and consolidation activity ahead for the U.S. cannabis market,” said Zuber. To prepare, sophisticated cannabis companies are pursuing IP protection strategies and making sure accounting records are pristine, he said, to make them more attractive targets for acquisition.
“Our initial round of seed funding has allowed us the ability to further invest in research and new product development as we expand our geographical reach of our Phytocine ™ and Rehab RX ™ brands. The passage of the US 2018 Farm Bill signed by President Trump at the end of 2018 will now allow Phyto Pharma to expand our hemp biomass cultivation from raw material extraction to consumer products containing specific genetic strains and IP owned by the Company. Phyto Pharma can now legally grow channels of distribution to multiple jurisdictions allowing delivery of hemp-derived products across state lines for both commercial and consumer use," stated Phillip Johnston, Esq., CEO of Phyto Pharma.
Legalization and acceptance of CBD for its health and wellness benefits is accelerating at a rapid pace globally. CBD is presently most commonly being used for anxiety, insomnia, pain and nausea, but is being investigated as a treatment for other conditions. Earlier this year, the U.S. FDA approved the CBD drug, Epidiolex, for the treatment of childhood epilepsy. The World Health Organization has also recommended descheduling CBD as a controlled substance among its 194-member states. The Brightfield Group of Chicago forecasts the market for CBD from hemp could reach US$22 billion by 2022.
Phyto Pharma is not making specific therapeutic claims. The use of the term pharmaceutical, pharmaceutical grade, pharmaceutical dosage forms, etc. are indicative of the process by which new formulation products will be created with the intent of accurately identifying specific strains, the active ingredients and measured amount to be used in each dosage form using best practices associated with traditional pharmacy formulations. Phyto Pharma is seeking to take existing anecdotal evidence and through its own formulation process further identify which cannabis varieties and strains are best suited to aid in a specific disease. The goal is to provide a reliable clinical effect through the use of well-crafted and well-researched oil analytics and dosage forms including oral and transdermal delivery of IP mapped cannabis extracts and nutraceutical and pharma brands.
About Phyto Pharma Inc.
Phyto Pharma Inc. ( www.Phytopharma.ca ) is a phytopharmaceutical and intellectual property holding company that has been created to develop innovative cannabis products, using accepted pharmaceutical formulation techniques, to reliably produce identifiable and replicable dosage forms for human use. The Company uses current Good Manufacturing Practices (cGMP) that would include pre-formulation, formulation development, small scale commercial manufacturing, analytical method development and validation, routine quality control analysis, and stability studies. It is Phyto Pharma’s intent to position itself to have safe, reliable, proven products ready for Phase I formulations when such trials become available and to improve the human condition and better the lives of those who suffer from disease.
Forward Looking Statements. Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of Phyto Pharma Inc., including, but not limited to the impact of general economic conditions, industry conditions, volatility of commodity prices, currency fluctuations, dependence upon regulatory approvals, the availability of future financing and exploration risk, the legality of cannabis and hemp. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements.
Contact: Phyto Pharma, Inc. www.phytopharma.ca email: info@phytopharma.ca 1500 West Georgia Suite # 1300 Vancouver BC V6G 2Z6 Canada PH: 778.373.4877
